Log inSign up
AAOIFI No. 21 screening

Is KAPA halal?

Kairos Pharma, Ltd.

Doubtful

No clear verdict is possible for Kairos Pharma, Ltd. — data is insufficient or the case is contested in fiqh. As a precaution it is NOT included in the halal list.

Checked: 14 October 2026

Exchange

AMEX

Price

0.6013

Day

-10.33%

Market cap

$2.6M

Industry

Biotechnology

Sector

Healthcare

What the company does

Kairos Pharma develops antibody and small-molecule drugs for prostate, lung and breast cancer (ENV-105 and others), clinical stage. Pre-revenue.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $0 ÷ 36-month average market cap $15.18M = 0.0%

    0.0%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $2.63M ÷ 36-month average market cap $15.18M = 17.3%

    17.3%

    Pass

  • Non-compliant income / total revenue

    limit 5%

    —

    No data

Figures from the company's filings (2026-06-30), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict. Today's market cap: $2.56M.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Biotechnology — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.

Earnings historyKAPA's next report date, EPS estimate vs actual for recent quarters and the post-earnings price move.View earnings →